Expanded FDA indications and Medicare coverage of semaglutide for cardiovascular risk prevention were associated with increased Wegovy utilization, most notably through Medicare Part D.
Dima Mazen Qato, PharmD, PhD, MPH
Advertisement
Articles by Dima Mazen Qato, PharmD, PhD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial
2
5 Things to Know About the FDA's Peptide Reversal
3
Iberdomide Complements CAR T in Myeloma: Swarup Kimar, MD
4
Escalation of Atopic Dermatitis Care Requires Addressing Barriers
5